Azafaros announces two executive appointments

20 March 2023

Clinical-stage, Netherlands-based biotech company Azafaros today announced two appointments to its executive management team.

Silvia Ragno joins the company as chief operating officer (COF) and Henrik Torp Nielsen as head of finance. With 35 years of combined experience in the pharmaceutical industry, they join as Azafaros prepares to start a Phase II clinical study, the RAINBOW study, with its lead asset AZ-3102, treating, for the first time, patients with GM2 gangliosidosis and Niemann-Pick disease type C.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK